Galectin-9与多种恶性肿瘤的研究进展及作用机制探讨

doi:10.11904/j.issn.1002-3070.2018.02.014

Abstract

Abstract: Galectin-9 is a member of galectin,with chemotaxis eosinophils,regulating cell aggregation and adhesion,immune regulation and other functions.In recent years,many studies have shown that Galectin-9 plays an important role in a variety of malignant tumors,affecting tumor cell proliferation,apoptosis and other activities.This article focuses on the relationship between Galectin-9 and various malignant tumors,and explores its possible mechanism of action.

Key words: Galectin-9, Malignant tumors, Mechanism

CLC Number:

R730

ZHANG Yongxin, HUANG He. Research progress and mechanism of Galectin-9 and various malignant tumors[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 159-163.

References

1 Madireddi S,Eun SY,Mehta AK,et al.Regulatory T cell-mediated suppression of inflammation induced by DR3 signaling is dependent on Galectin-9[J].J Immunol,2017,199(8):2721-2728.
2 Liu Z,Han H,He X,et al.Expression of the Galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma[J].Oncol Lett,2016,11(3):1829-1834.
3 Asayama T,Tamura H,Ishibashi M,et al.Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes[J].Oncotarget,2017,8(51):88904-88917.
4 Arikawa T,Saita N,Oomizu S,et al.Galectin-9 expands immunosuppressive macrophages to ameliorate T-cell-mediated lung inflammation[J].Eur J Immunol,2010,40(2):548-558.
5 Choi SI,Seo KW,Kook MC,et al.Prognostic value of tumoral expression of galectin-9 in gastric cancer[J].Turk J Gastroenterol,2017,28(3):166-170.
6 Yang J,Zhu L,Cai Y,et al.Role of downregulation of Galectin-9 in the tumorigenesis of gastric cancer[J].Int J Oncol,2014,45(3):1313-1320.
7 Jiang J,Jin MS,Kong F,et al.Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer[J].PLoS One,2013,8(12):e81799.
8 Wang Y,Sun J,Ma C,et al.Reduced expression of Galectin-9 contributes to a poor outcome in colon cancer by inhibiting NK cell chemotaxis partially through the Rho/ROCK1 signaling pathway[J].PLoS One,2016,11(3):e0152599.
9 Punt S,Thijssen VL,Vrolijk J,et al.Galectin-1,-3 and-9 expression and clinical significance in squamous cervical cancer [J].PLoS One,2015,10(6):e0129119.
10 Schulkens IA,Heusschen R,van den Boogaart V,et al.Galectin expression profiling identifies galectin-1 and Galectin-9Δ5 as prognostic factors in stage Ⅰ/Ⅱ non-small cell lung cancer[J].PLoS One,2014,9(9):e107988.
11 Kim SN,Lee HJ,Jeon MS,et al.Galectin-9 is involved in immunosuppression mediated by human bone marrow-derived clonal mesenchymal stem cells[J].Immune Netw,2015,15(5):241-251.
12 Da Silva TA,Oliveira-Brito PKM,Goncalves TE,et al.ArtinM mediates murine T cell activation and induces cell death in Jurkat human leukemic T cells[J].Int J Mol Sci,2017,30;18(7):1400.
13 Kobayashi T,Kuroda J,Ashihara E,et al.Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways[J].Leukemia,2010,24(4):843-850.
14 Kuroda J,Yamamoto M,Nagoshi H,et al.Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia[J].Mol Cancer Res,2010,8(7):994-1001.
15 Wiersma VR,de Bruyn M,van Ginkel RJ,et al.The glycan-binding protein galectin-9 has direct apoptotic activity toward melanoma cells[J].J Invest Dermatol,2012,132(9):2302-2305.
16 Wang Z,Yin N,Zhang Z,et al.Upregulation of T-cell immunoglobulin and Mucin-Domain Containing-3(Tim-3)in monocytes/macrophages associates with gastric cancer progression[J].Immunol Invest,2017,46(2):134-148.
17 Takano J,Morishita A,Fujihara S,et al.Galectin-9 suppresses the proliferation of gastric cancer cells in vitro[J].Oncol Rep,2016,35(2):851-860.
18 Kobayashi K,Morishita A,Iwama H,et al.Galectin-9 suppresses cholangiocarcinoma cell proliferation by inducing apoptosis but not cell cycle arrest[J].Oncol Rep,2015,34(4):1761-1770.
19 Tadokoro T,Morishita A,Fujihara S,et al.Galectin-9:An anticancer molecule for gallbladder carcinoma[J].Int J Oncol,2016,48(3):1165-1174.
20 Tadokoro T,Fujihara S,Chiyo T,et al.Induction of apoptosis by Galectin-9 in liver metastatic cancer cells:In vitro study[J].Int J Oncol,2017,51(2):607-614.
21 Akashi E,Fujihara S,Morishita A,et al.Effects of galectin-9 on apoptosis,cell cycle and autophagy in human esophageal adenocarcinoma cells[J].Oncol Rep,2017,38(1):506-514.
22 Fujita K,Iwama H,Oura K,et al.Cancer therapy due to apoptosis:Galectin-9[J].Int J Mol Sci.2017,18(1):74.
23 Fujihara S,Mori H,Kobara H,et al.Galectin-9 in cancer therapy.[J]Recent Pat Endocr Metab Immune Drug Discov,2013,7(2):130-137.
24 Zhao J,Shiratori B,Chagan-Yasutan H,et al.Secretion of IFN-γ associated with Galectin-9 production by pleural fluid cells from a patient with extra pulmonary tuberculosis[J].Int J Mol Sci,2017,18(7):1382.
25 Alam S,Li H,Margariti A,et al.Galectin-9 protein expression in endothelial cells is positively regulated by histone deacetylase 3[J].J Biol Chem,2011,286(51):44211-44217.
26 Zhang F,Zheng MH,Qu Y,et al.Galectin-9 isoforms influence the adhesion between colon carcinoma LoVo cells and human umbilical vein endothelial cells in vitro by regulating the expression of E-selectin in LoVo cells[J].Zhonghua Zhong Liu Za Zhi,2009,31(2):95-98.
27 Kageshita T,Kashio Y,Yamauchi A,et al.Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance[J].Int J Cancer,2002,99(6):809-816.
28 Irie A,Yamauchi A,Kontani K,et al.Galectin-9 as a prognostic factor with an time tastatic potential in breast cancer[J].Clin Cancer Res,2005,11(8):2962-2968.
29 Cho SJ,Kook MC,Lee JH,et al.Peroxisome proliferator-activated receptor γ upregulates galectin-9 and predicts prognosis in intestinal-type gastric cancer[J].Int J Cancer,2015,136(4):810-820.
30 Nobumoto A,Nagahara K,Oomizu S,et al.Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices[J].Glycobiology,2008,18(9):735-744.
31 Thijssen VL,Heusschen R,Caers J,et al.Galectin expression in cancer diagnosis and prognosis:A systematic review[J].Biochim Biophys Acta,2015,1855(2):235-247.
32 John S,Mishra R.Galectin-9:From cell biology to complex disease dynamics[J].J Biosci,2016,41(3):507-534.
33 Chang WA,Tsai MJ,Kuo PL,et al.Role of galectins in lung cancer[J].Oncol Lett,2017,14(5):5077-5084.
34 Yang R,Hung MC.The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy[J].Sci China Life Sci,2017,60(10):1058-1064.
35 Kursunel MA,Esendagli G.A co-inhibitory alliance in myeloid leukemia:Tim-3/Galectin-9 complex as a new target for checkpoint blockade therapy[J].E Bio Medicine,2017,23:6-7.
36 Nagahara K,Arikawa T,Oomizu S,et al.Galectin-9 increases Tim-3+ dendritic cells and CD8⁺T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions[J].J Immunol,2008,181(11):7660-7769.
37 Kadowaki T,Arikawa T,Shinonaga R,et al.Galectin-9 signaling prolongs survival in murine lung-cancer by inducing macrophages to differentiate into plasmacytoid dendritic cell-like macrophages[J].Clin Immunol,2012,142(3):296-307.
38 Clayton KL,Haaland MS,Douglas-Vail MB,et al.T cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse,disrupts stable synapse formation,and associates with receptor phosphatases[J].J Immunol,2014,192(2):782-791.
39 Nobumoto A,Oomizu S,Arikawa T,et al.Galectin-9 expands unique macrophages exhibiting plasmacytoid dendritic cell-like phenotypes that activate NK cells in tumor-bearing mice[J].Clin Immunol,2009,130(3):322-330.
40 Nagahara K,Arikawa T,Oomizu S,et al.Galectin-9 increases Tim-3+ dendritic cells and CD8⁺T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions[J].J Immunol,2008,181(11):7660-7609.
41 Yang Q,Hou C,Huang D,et al.MiR-455-5p functions as a potential oncogene by targeting galectin-9 in colon cancer[J].Oncol Lett,2017,13(3):1958-1964.
42 Fujita K,Iwama H,Sakamoto T,et al.Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo[J].Int J Oncol,2015,46(6):2419-2430.

[1]	CHANG Xiaoxia, SONG Bingbing, LIU Jiaren. Research progress in phytochemicals for increasing sensitivity of tumor cells to chemotherapies [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 67-72.
[2]	KAN Jun, ZHOU Daihan, ZHANG Enxin. Research progress in tumor with cardiovascular disease [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 558-561.
[3]	WANG Yuan, SUN Yihua. Advance in the role of β-catenin in soft tissue tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 455-459.
[4]	FAN Ningning, GENG Jingshu. The expression and role of LncRNA MEG3 in human glioma cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 219-223.
[5]	ZHOU Jie, CHEN Yu, CHEN Daozhen. Application of nanoparticles in photodynamic therapy of tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 245-249.
[6]	HAN Xuejiao, LI Yanchun, SUN lichun, LU Hailing. Research progress of the relationship between 14-3-3ζ and malignant tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 543-547.
[7]	JIN Tuan, ZHANG Qingyuan. Research propress in signaling pathways and molecular mechanisms of brain metastases in breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 468-471.
[8]	YUAN Meng,LI Xiaoli. Research progress of the relationship between TRAP1 and malignant tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 371-375.
[9]	ZENG Kai,LIU Ming. Research progress of CBX protein and tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 165-169.
[10]	CHAI Jingbo, LI Ping, PEI Zhiping. The effects and mechanism of Lycopene on immune function of ovarian cancer rats [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 13-17.
[11]	FAN Mingxv, ZHAO Yanbin, LI Boyang, WANG Yan. Research progress in the Notch pathway in malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 57-60.
[12]	HOU Yangming, XU Yingjuan, CUI Yunfu. Advances in the tumor related research of IRF-4 binding protein [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 93-96.
[13]	WANG Peng, WANG Zheng, ZHOU Zhixiang. Roles of p53 in the interaction with digestive malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(5): 468-472.
[14]	ZHANG Wei,WU Jin. The research progress on cancer multidrug resistance mechanisms [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(4): 364-367.
[15]	HUANG Dongning,LIANG Xiaona,CHEN Gang. Progress in the study of lncRNA in the colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(3): 263-266.

Research progress and mechanism of Galectin-9 and various malignant tumors

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments